Analysts reiterate Buy on Corcept after EMA CHMP support
EMA CHMP backed relacorilant plus nab—paclitaxel for platinum—resistant ovarian cancer; HC Wainwright reiterated Buy and a $165 target, implying ~43.7% upside ahead of an EU decision.
EMA CHMP backed relacorilant plus nab—paclitaxel for platinum—resistant ovarian cancer; HC Wainwright reiterated Buy and a $165 target, implying ~43.7% upside ahead of an EU decision.